MEI Pharma Analyst Ratings
MEI Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/13/2023 | 599.3% | HC Wainwright & Co. | $5 → $2 | Maintains | Buy |
| 02/08/2023 | -65.03% | Jefferies | $0.4 → $0.1 | Downgrades | Hold → Underperform |
| 12/06/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | 1298.6% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | 948.95% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | 1648.25% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | 599.3% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | 599.3% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | 249.65% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | 1298.6% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 5494.41% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 3396.5% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/27/2018 | 2347.55% | Stifel | $2.5 → $7 | Upgrades | Hold → Buy |
| 07/13/2018 | 4095.8% | SunTrust Robinson Humphrey | → $12 | Initiates Coverage On | → Buy |
| 06/06/2018 | — | Wells Fargo | Upgrades | Market Perform → Outperform | |
| 04/12/2018 | 2347.55% | Laidlaw & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/13/2023 | 599.3% | HC Wainwright公司 | $5→$2 | 維護 | 買 |
| 02/08/2023 | -65.03% | 傑富瑞 | $0.4→$0.1 | 評級下調 | 持有→表現不佳 |
| 12/06/2022 | - | BTIG | 評級下調 | 購買→中性 | |
| 12/06/2022 | - | Truist證券 | 評級下調 | 購買→Hold | |
| 03/25/2022 | 1298.6% | BTIG | $11→$4 | 維護 | 買 |
| 03/25/2022 | 948.95% | Truist證券 | $8→$3 | 維護 | 買 |
| 03/25/2022 | 1648.25% | HC Wainwright公司 | $10→$5 | 維護 | 買 |
| 03/25/2022 | 599.3% | 富國銀行 | $13→$2 | 評級下調 | 超重→等重 |
| 03/25/2022 | 599.3% | Stifel | $6→$2 | 評級下調 | 購買→Hold |
| 03/25/2022 | 249.65% | 傑富瑞 | $4→$1 | 評級下調 | 購買→Hold |
| 02/03/2022 | 1298.6% | 傑富瑞 | →$4 | 開始承保 | →購買 |
| 05/29/2020 | 5494.41% | SunTrust Robinson Humphrey | →$16 | 開始承保 | →購買 |
| 2019年02月13日 | - | BTIG | 開始承保 | →購買 | |
| 2018年12月20日 | 3396.5% | HC Wainwright公司 | →$10 | 開始承保 | →購買 |
| 2018年07月27日 | 2347.55% | Stifel | $2.5→$7 | 升級 | 持有→購買 |
| 2018年07月13日 | 4095.8% | SunTrust Robinson Humphrey | →$12 | 開始承保 | →購買 |
| 2018/06/06 | - | 富國銀行 | 升級 | 市場表現優於→ | |
| 2018年4月12日 | 2347.55% | 萊德勞公司 | →$7 | 開始承保 | →購買 |
What is the target price for MEI Pharma (MEIP)?
美藥(MEIP)的目標價是多少？
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by HC Wainwright & Co. on February 13, 2023. The analyst firm set a price target for $2.00 expecting MEIP to rise to within 12 months (a possible 599.30% upside). 10 analyst firms have reported ratings in the last year.
納斯達克(Meituan：MEIP)的最新目標價是由HC Wainwright&Co.於2023年2月13日報道的。這家分析公司將目標價定為2美元，預計MEIP將在12個月內上漲至(可能上漲599.30%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for MEI Pharma (MEIP)?
美藥(Mei Pharma)最近的分析師評級是多少？
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by HC Wainwright & Co., and MEI Pharma maintained their buy rating.
美藥(納斯達克代碼：MEIP)的最新分析師評級由HC Wainwright&Co.提供，美藥維持買入評級。
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
美醫藥(MEIP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on February 13, 2023 so you should expect the next rating to be made available sometime around February 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，這些研究包括查看公開的財務報表，與美藥的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。美醫藥的上一次評級是在2023年2月13日提交的，所以你應該預計下一次評級將在2024年2月13日左右的某個時候公佈。
Is the Analyst Rating MEI Pharma (MEIP) correct?
分析師對美醫藥(Mei Pharma)的評級正確嗎？
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $5.00 to $2.00. The current price MEI Pharma (MEIP) is trading at is $0.29, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的美藥(MEIP)評級維持不變，目標價在5.00美元至2.00美元之間。美藥(Mei Pharma)目前的交易價格為0.29美元，超出了分析師的預測區間。